CELLECT BIOTECH/S (APOP) & Cardiovascular Systems (CSII) Financial Review

Share on StockTwits

CELLECT BIOTECH/S (NASDAQ: CSII) and Cardiovascular Systems (NASDAQ:CSII) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

Risk & Volatility

CELLECT BIOTECH/S has a beta of 3.6, meaning that its share price is 260% more volatile than the S&P 500. Comparatively, Cardiovascular Systems has a beta of 2.45, meaning that its share price is 145% more volatile than the S&P 500.


This table compares CELLECT BIOTECH/S and Cardiovascular Systems’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CELLECT BIOTECH/S N/A -93.06% -60.94%
Cardiovascular Systems 0.79% 1.36% 0.88%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for CELLECT BIOTECH/S and Cardiovascular Systems, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CELLECT BIOTECH/S 0 0 1 0 3.00
Cardiovascular Systems 0 4 4 0 2.50

CELLECT BIOTECH/S currently has a consensus price target of $14.00, suggesting a potential upside of 181.69%. Cardiovascular Systems has a consensus price target of $37.00, suggesting a potential downside of 3.09%. Given CELLECT BIOTECH/S’s stronger consensus rating and higher probable upside, equities analysts plainly believe CELLECT BIOTECH/S is more favorable than Cardiovascular Systems.

Valuation and Earnings

This table compares CELLECT BIOTECH/S and Cardiovascular Systems’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CELLECT BIOTECH/S N/A N/A -$8.14 million ($1.46) -3.40
Cardiovascular Systems $217.04 million 5.89 $1.71 million $0.05 763.60

Cardiovascular Systems has higher revenue and earnings than CELLECT BIOTECH/S. CELLECT BIOTECH/S is trading at a lower price-to-earnings ratio than Cardiovascular Systems, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

3.7% of CELLECT BIOTECH/S shares are owned by institutional investors. Comparatively, 85.2% of Cardiovascular Systems shares are owned by institutional investors. 3.3% of Cardiovascular Systems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.


Cardiovascular Systems beats CELLECT BIOTECH/S on 10 of the 13 factors compared between the two stocks.


Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company was founded in 2011 and is headquartered in Kfar Saba, Israel.

Cardiovascular Systems Company Profile

Cardiovascular Systems, Inc., a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives. It also provides Diamondback 360 Coronary OAS, an atherectomy device for the treatment of calcified coronary arteries. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.

Receive News & Ratings for CELLECT BIOTECH/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELLECT BIOTECH/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply